Weight Management News and Research

RSS

Chrononutrition shows promise for postpartum weight management

New research has found that eating habits that align most closely with a woman's existing routine show promise for losing postpartum baby weight, especially for mothers earlier in the postpartum period.

20 Jul 2026

Diet helps people lose weight regardless of genetic obesity risk

A study reveals dietary coaching aids weight loss equally in individuals with high and low genetic obesity risk, challenging genetic determinism in weight loss.

17 Jul 2026

Study links expanding GLP-1 use with rising overall costs

As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022.

16 Jul 2026

Blood ketone threshold may help predict weight loss success

Achieving and sustaining a blood ketone level of 0.5 mmol/L is crucial for weight loss in ketogenic diets, offering a new approach to dietary monitoring.

16 Jul 2026

Semaglutide dose may matter more than weight loss for heart health

The study shows semaglutide's cardiovascular benefits are more closely tied to attained dose than weight loss, challenging existing treatment assumptions.

14 Jul 2026

Nearly one in 10 Britons use or want weight-loss medication

The prevalence of GLP-1 receptor agonists for weight management in Great Britain highlights public interest and concerns over safety and prescribing practices.

13 Jul 2026

GLP-1RAs linked to lower risk of amputation in diabetes with PAD

Research indicates GLP-1RAs may decrease limb complications in type 2 diabetes with PAD, though more randomized studies are required to confirm efficacy.

10 Jul 2026

Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated weight-loss effect among GLP-1 receptor agonists tested in adults with mental illness and obesity or related metabolic risk. The authors cautioned that the findings remain preliminary because the evidence base was small, heterogeneous, and largely indirect.

9 Jul 2026

Obesity makes breathing harder during exercise for young vapers

E-cigarette users with obesity show higher ventilatory demands and breathlessness during exercise, indicating potential long-term respiratory health risks.

30 Jun 2026

Pharmacy expert calls for hybrid digital-human models in NHS healthcare

A pharmacy academic from Kingston University has provided special expertise to the UK Parliament on two key Health and Social Care Committee inquiries.

30 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

Lost weight is less likely to return when exercise follows obesity treatment

A systematic review and meta-analysis of 11 randomized controlled trials found that exercise during the post-weight-loss maintenance phase reduced weight regain by an average of 2.81 kg compared with control groups. Evidence for fat-mass reduction remained inconclusive, highlighting the need for longer, standardized trials with better adherence and body-composition monitoring.

24 Jun 2026

Researchers trace soaring poison control calls to semaglutide approval for weight loss

When semaglutide's popularity exploded following FDA approval for weight management in 2021, so too did a wave of calls to poison control centers.

23 Jun 2026

Experts outline a multidisciplinary approach to managing clinical obesity

The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment.

17 Jun 2026

Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously recognized in major consensus reports. The study also reveals regional and sex-based variation in cancer risk, with genetic evidence generally supporting many observational links while highlighting the need for more diverse global cohorts.

17 Jun 2026

Study identifies top predictors for weight loss using tirzepatide

One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting a weight goal were the best predictors of total weight loss, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

16 Jun 2026

Testosterone benefits older men with T2D risk when combined with lifestyle changes

Testosterone treatment may improve body composition, glucose metabolism and sexual desire in some older men at high risk of type 2 diabetes (T2D), but the benefits require engagement in a lifestyle program, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026